The assignment of a permanent J-Code is a significant regulatory milestone for pharmaceutical and therapy products. It simplifies the reimbursement process for healthcare providers, making the product more attractive and easier to use. This typically leads to increased adoption and sales, which is why the news is likely to have a positive impact on Delcath Systems' stock price in the short term. The high relevance score is due to the direct mention of Delcath Systems and the importance of the J-Code to its product, HEPZATO. The importance score reflects the potential for increased revenue, while the confidence score is high due to the clear positive nature of regulatory approvals on company prospects.